# OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)

> **NCT00097422** · PHASE2 · COMPLETED · sponsor: **Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)**

## Conditions studied

- Diarrhea

## Interventions

- **DRUG:** OPT-80

## Key facts

- **NCT ID:** NCT00097422
- **Lead sponsor:** Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11-01
- **Primary completion:** 2005-04-01
- **Final completion:** 2005-04-01
- **Target enrollment:** — (—)
- **Last updated:** 2017-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00097422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00097422, "OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00097422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*